<DOC>
	<DOCNO>NCT00021281</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . SU5416 may stop growth tumor cell stop blood flow tumor . It yet know whether combination chemotherapy effective without SU5416 treat metastatic colorectal cancer . PURPOSE : Randomized phase III trial compare effectiveness combination chemotherapy without SU5416 treat patient metastatic colorectal cancer .</brief_summary>
	<brief_title>Combination Chemotherapy With Without SU5416 Treating Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare survival patient previously untreated metastatic colorectal cancer treat fluorouracil , leucovorin calcium , irinotecan without SU5416 . II . Compare antitumor efficacy regimens patient . III . Evaluate additional measure clinical benefit patient treat regimen . IV . Determine relative safety profile regimens patient . V. Assess quality life patient treat regimen . OUTLINE : This randomize , open-label , multicenter study . Patients stratify accord ECOG performance status ( 0 vs 1 ) , baseline lactate dehydrogenase ( normal v elevate ) , treatment regimen . Patients randomize 1 2 treatment arm 2 different regimen ( Saltz v de Gramont ) . Regimen I ( Saltz ) : Arm IA : Patients receive SU5416 IV 1 hour day 1 , 4 , 8 , 11 , 15 , 18 , 22 , 25 , 29 , 32 , 36 , 39 . Patients also receive irinotecan IV 30-90 minute , leucovorin calcium IV 5-10 minute , fluorouracil IV 5-10 minute day 1 , 8 , 15 , 22 . Arm IIA : Patients receive irinotecan , leucovorin calcium , fluorouracil arm I . Treatment arm repeat every 6 week absence disease progression unacceptable toxicity . Regimen II ( de Gramont ) : Arm IB : Patients receive SU5416 arm IA . Patients also receive irinotecan IV 30-90 minute day 1 , 15 , 29 leucovorin calcium IV 2 hour fluorouracil IV 2 hour day 1 , 2 , 15 , 16 , 29 , 30 . Arm IIB : Patients receive irinotecan , leucovorin calcium , fluorouracil arm IB . Treatment arm repeat every 6 week absence disease progression unacceptable toxicity . Quality life assess baseline , begin course , end treatment . Patients follow 1 month every 2 month 4 year . PROJECTED ACCRUAL : A total 1,270 patient ( 635 per treatment arm ) accrue study within 2 year .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Semaxinib</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma colon rectum Newly diagnose recurrent disease Measurable evaluable metastatic disease previously untreated No known brain leptomeningeal metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 8.0 g/dL Hepatic : Bilirubin great 1.8 time upper limit normal ( ULN ) SGOT great 5 time ULN Alkaline phosphatase great 5 time ULN Lactate dehydrogenase great 5 time ULN Renal : Creatinine great 1.5 time ULN Cardiovascular : No myocardial infarction within past 6 month No ongoing unstable angina No symptomatic congestive heart failure No serious uncontrolled cardiac dysrhythmia No stroke within past 6 month Gastrointestinal : No active inflammatory bowel disease No significant bowel obstruction No chronic diarrhea grade 2 great Other : HIV negative No AIDSrelated illness No known allergy Cremaphorcontaining product , irinotecan , fluorouracil , warfarin ( similar oral anticoagulant ) lowmolecular weight heparin No malignancy within past 5 year except nonmelanoma skin cancer No severe acute chronic medical psychiatric condition laboratory abnormality would preclude study Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : At least 6 month since prior adjuvant antibody therapy , immunotherapy , gene therapy , vaccine therapy , cytokine therapy No prior systemic biologic therapy metastatic disease , include antibody therapy , immunotherapy , gene therapy , vaccine therapy , cytokine therapy , angiogenesis inhibitor ( e.g. , SU5416 , matrix metalloprotease inhibitor , thalidomide , antiVEGF/Flk1 monoclonal antibody ) No concurrent antibody therapy , immunotherapy , gene therapy , vaccine therapy , angiogenesis inhibitor No concurrent sargramostim ( GMCSF ) Chemotherapy : At least 6 month since prior adjuvant chemotherapy ( e.g. , fluorouracil , leucovorin calcium , levamisole , irinotecan , oxaliplatin , capecitabine , fluorouraciluracil , cytotoxic agent ) No prior systemic chemotherapy metastatic disease No prior intraarterial cytotoxic chemotherapy metastatic disease No concurrent chemotherapy Endocrine therapy : No concurrent anticancer hormonal therapy Radiotherapy : At least 6 month since prior adjuvant radioimmunotherapy radiotherapy recover No concurrent radiotherapy Surgery : Recovered prior surgery Other : At least 6 month since prior adjuvant therapy No prior systemic anticancer therapy metastatic disease No concurrent anticancer therapy No concurrent experimental drug No concurrent participation another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2001</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma rectum</keyword>
</DOC>